- Home
- AGIO vs PRGS Comparison
AGIO vs PRGS Comparison
Compare AGIO & PRGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- PRGS
- Stock Information
- Founded
- AGIO 2007
- PRGS 1981
- Country
- AGIO United States
- PRGS United States
- Employees
- AGIO N/A
- PRGS N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- PRGS Computer Software: Prepackaged Software
- Sector
- AGIO Health Care
- PRGS Technology
- Exchange
- AGIO Nasdaq
- PRGS Nasdaq
- Market Cap
- AGIO 2.0B
- PRGS 2.4B
- IPO Year
- AGIO 2013
- PRGS 1991
- Fundamental
- Price
- AGIO $30.28
- PRGS $51.39
- Analyst Decision
- AGIO Buy
- PRGS Buy
- Analyst Count
- AGIO 8
- PRGS 8
- Target Price
- AGIO $56.57
- PRGS $72.13
- AVG Volume (30 Days)
- AGIO 637.9K
- PRGS 684.6K
- Earning Date
- AGIO 05-01-2025
- PRGS 03-31-2025
- Dividend Yield
- AGIO N/A
- PRGS 0.68%
- EPS Growth
- AGIO N/A
- PRGS N/A
- EPS
- AGIO 11.64
- PRGS 1.54
- Revenue
- AGIO $36,498,000.00
- PRGS $753,409,000.00
- Revenue This Year
- AGIO $50.61
- PRGS $30.56
- Revenue Next Year
- AGIO $223.79
- PRGS $3.29
- P/E Ratio
- AGIO $2.60
- PRGS $33.37
- Revenue Growth
- AGIO 36.07
- PRGS 8.49
- 52 Week Low
- AGIO $27.14
- PRGS $48.00
- 52 Week High
- AGIO $62.58
- PRGS $70.56
- Technical
- Relative Strength Index (RSI)
- AGIO 39.54
- PRGS 31.95
- Support Level
- AGIO $30.00
- PRGS $53.74
- Resistance Level
- AGIO $32.90
- PRGS $55.74
- Average True Range (ATR)
- AGIO 1.22
- PRGS 1.32
- MACD
- AGIO -0.08
- PRGS -0.16
- Stochastic Oscillator
- AGIO 9.12
- PRGS 0.81
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About PRGS Progress Software Corporation (DE)
Progress Software Corporation provides software operate in one operating segment: software products for the development, deployment, and management of responsible, AI-powered applications and digital experiences. Following are products: Chef, Corticon, Data Direct, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, WhatsUp Gold. Geographical regions include United States, Canada, EMEA, Latin America, and Asia Pacific.